Histone deacetylase inhibitors in treatment of hematological malignancies
10.3760/cma.j.issn.1009-9921.2016.12.001
- VernacularTitle:组蛋白去乙酰化酶抑制剂在血液系统肿瘤治疗中的研究进展
- Author:
Ke SHI
;
Yi MIAO
;
Jianyong LI
- Keywords:
Lymphoma;
Multiple myeloma;
Leukemia;
Histone deacetylase inhibitor;
American Society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(12):705-708
- CountryChina
- Language:Chinese
-
Abstract:
Histone deacetylase inhibitor (HDACi) is a novel antineoplastic agent emerging in recent years. The advent of HDACi has provided new options for the treatment of malignant tumors, parasitic and inflammatory diseases. HDACi, as single agent or in combination with other drugs, has a considerable prospect in the treatment of hematological malignancies. The use of HDACi in the treatment of hematological malignancies will be summarized in this paper based on the reports in the 58th ASH Annual Meeting.
